AVNT: Higher Crude Driven Commodity Margins Will Support Future ReRating Potential

Analysts reduced their price target on Avient by about $1 to reflect lower assumed future P/E multiples, even as updated assumptions point to slightly different expectations for revenue growth, profit margins and discount rates, alongside recent sector-wide rating changes and commodity margin views in the chemicals space.

Analyst Commentary

Recent research commentary on Avient has focused on how geopolitical risks, commodity cost trends and changing assumptions for valuation multiples are feeding into updated views on the stock.

Bullish Takeaways

Bullish analysts see potential upside risk to commodity margins over the next few quarters as rising crude oil prices lift the global cost curve, which could support earnings power if Avient can pass through higher raw material costs.
Some commentary frames the current period as part of a broader "commodities playbook," suggesting that a stronger pricing backdrop for petrochemical inputs might offer a tailwind for volume and pricing resilience.
Where upside to commodity margins is highlighted, bullish analysts point to the possibility that Avient could benefit if its product mix and contracts allow it to capture some of the spread between input costs and selling prices.

Bearish Takeaways

Bearish analysts emphasize rising raw material costs as a key concern, arguing that higher feedstock prices could compress margins if Avient faces delays or limits in passing through cost increases.
The shift in sector ratings tied to the Iran war "commodities playbook" has included Avient in a more cautious bucket, with some viewing the risk reward as less attractive relative to other U.S. petrochemical exposures.
Lower assumed future P/E multiples in recent models indicate a more conservative stance on how much investors may be willing to pay for Avient's earnings, even if underlying commodity trends offer some potential upside.
The absence of a new explicit price target in at least one downgrade underscores a focus on execution risk around cost inflation and margin resilience rather than on pinpoint valuation upside.

What's in the News

Avient announced that Giuseppe (Joe) Di Salvo has been promoted and named Chief Financial Officer, effective June 1, 2026. Source: company key developments.
Di Salvo will succeed current CFO Jamie A. Beggs, who is set to leave Avient on June 1, 2026 to pursue other opportunities. Source: company key developments.
Di Salvo brings 25 years of financial experience, including nearly 15 years at Avient across investor relations, accounting, financial planning and analysis, and treasury roles. Source: company key developments.
His prior roles at Avient include Corporate Controller from 2013 to 2018 and later Vice President, Investor Relations, with added responsibility for Treasury and Financial Planning and Analysis from 2019. Source: company key developments.
Di Salvo began his career as a certified public accountant at Deloitte after graduating from The Ohio State University Fisher College of Business with a Bachelor of Science in Business Administration and Accounting. Source: company key developments.

Valuation Changes

Fair value was trimmed from $48.57 to $47.57, a reduction of about 2.1%.
The discount rate was adjusted slightly lower from 8.31% to 8.26%, indicating a modest change in the assumed risk profile used in the model.
Revenue growth was raised from 3.53% to 3.83%, reflecting a small uplift in expected top line expansion.
Net profit margin was increased from 7.28% to 8.43%, pointing to higher modeled profitability on future dollar revenue.
The future P/E multiple was reduced from 21.31x to 17.94x, signaling a more conservative view on how much investors may pay for each dollar of Avient's earnings.

0 views

Key Takeaways

Expansion into high-value healthcare and sustainable materials, plus strong innovation, positions Avient for resilient growth, improved profit margins, and premium-product pricing.
Operational efficiencies and strategic debt reduction increase free cash flow, lower risk, and support ongoing investment in innovation and long-term value creation.
Secular declines in key markets, raw material volatility, regulatory and sustainability pressures, and over-reliance on select sectors threaten Avient's growth, profitability, and long-term valuation.

Catalysts

About Avient

Operates as a formulator of material solutions in the United States, Canada, Mexico, Europe, South America, and Asia.What are the underlying business or industry changes driving this perspective?

Accelerating demand for high-performance, specialty materials in healthcare devices, drug delivery, and equipment-driven by global healthcare expansion and innovative new product launches-positions Avient for resilient, long-term revenue growth and increased net margins due to higher-value, spec-in solutions.
Continued shift in customer and regulatory preferences toward eco-friendly lightweight polymers and sustainable materials, along with Avient's portfolio transformation and innovation in low-energy, circular products, supports future revenue expansion and structural improvement in EBITDA margins.
Enhanced R&D collaboration, evidenced by rising patent filings and successful proprietary product introductions, is expanding Avient's differentiated solutions pipeline-supporting higher gross profit and long-term earnings power as new products command premium pricing.
Ongoing footprint optimization, Lean Six Sigma initiatives, and discretionary spending controls are structurally lowering operating costs and improving productivity-leading to sustained improvements in EBITDA margins and higher free cash flow generation.
Strategic deleveraging of the balance sheet enables increased capacity for reinvestment in growth vectors like healthcare and sustainability, reducing financial risk and supporting stronger EPS growth and enterprise value over the long term.

Avient Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Avient's revenue will grow by 3.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 4.8% today to 8.4% in 3 years time.
Analysts expect earnings to reach $309.6 million (and earnings per share of $2.84) by about June 2029, up from $157.8 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 18.0x on those 2029 earnings, down from 20.1x today. This future PE is lower than the current PE for the US Chemicals industry at 26.4x.
Analysts expect the number of shares outstanding to grow by 0.19% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.26%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Sustained weakness and broad-based decline in consumer end-markets across all major geographies, with no near-term signs of improvement, could restrain top-line revenue growth and represent a structural risk if secular consumption patterns continue to shift away from traditional polymer-based goods.
Exposure to volatility and inflation in the raw material basket, especially pigments and flame retardants (a significant portion sourced from China), may lead to persistent cost pressure; inability to fully pass through these increases to customers could compress net margins and earnings.
Ongoing regulatory shifts, trade policy uncertainty, and potential supply constraints-particularly in China, where government-enforced consolidation and credit tightening disrupt supply chains-risk increasing input costs or reducing demand, jeopardizing revenue stability and profitability.
Dependence on strong performance in high-growth sectors like healthcare, defense, and telecom to offset persistent weakness in core markets introduces concentration risk; any deceleration or regulatory headwind in these sectors could quickly erode overall earnings momentum.
Continued broad investor, customer, and regulatory focus on sustainability might outpace Avient's innovation and portfolio transformation efforts; prolonged legacy exposure to non-sustainable or commodity polymers could limit contract wins and revenue scalability, raising the risk of long-term stagnation in net income and impairing valuation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $47.57 for Avient based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $52.0, and the most bearish reporting a price target of just $42.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.7 billion, earnings will come to $309.6 million, and it would be trading on a PE ratio of 18.0x, assuming you use a discount rate of 8.3%.
Given the current share price of $34.61, the analyst price target of $47.57 is 27.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Avient?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

High-Performance Healthcare Materials And Sustainable Polymers Will Create Value